Acalabrutinib for CLL in routine care in Belarus

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, observational, multi-center cohort that will collect real-world data on patients with CLL who start acalabrutinib monotherapy in Belarus. Patients will receive usual care with no study-mandated treatment changes, and clinicians will make all treatment decisions independently. Each patient will be followed for about two years with scheduled data collection on treatment exposure, clinical outcomes, adverse events, and quality of life. The goal is to describe effectiveness and safety of acalabrutinib in routine practice rather than to alter patient care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥18 years.
* Confirmed diagnosis of CLL.
* Newly prescribed acalabrutinib monotherapy within the previous four weeks preceding study enrolment. Monotherapy is defined as acalabrutinib prescribes without concomitant administration (or planned initiation) of other anti-leukemic agents (e.g. obinutuzumab, venetoclax, bendamustine) within ± 30 days of acalabrutinib initiation.
* Treatment-naïve or R/R CLL.
* Ability and willingness to provide informed consent for study participation.

Exclusion Criteria:

* Patients not satisfying any of the inclusion criteria.
* Prior treatment with any BTK inhibitor.
* Participation in other ongoing clinical trials.
* Pregnant or breastfeeding females

Where it's running

• Research Site
  Grodno, Belarus Recruiting
• Research Site
  Minsk, Belarus Recruiting
• Research Site
  Mogilev, Belarus Recruiting
• Research Site
  Homyel, Belarus Not yet recruiting

Study contacts

• Study coordinator: AstraZeneca Clinical Study Information Center
• Email: information.center@astrazeneca.com
• Phone: 1-877-240-9479

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tafasitamab plus Acalabrutinib and Venetoclax for newly treated CLL/SLL

  This phase II study tests a combination of tafasitamab, acalabrutinib, and venetoclax in adults who are newly diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma to see if it is safe and effective.

  Recruiting at 2 sites Phase 2 City of Hope Medical Center · Duarte, California and 1 other locations · NCT07582159

• Sonrotoclax plus zanubrutinib versus venetoclax plus acalabrutinib for adults with untreated CLL

  This tests whether a fixed-duration combination of sonrotoclax plus zanubrutinib works as well as or better than venetoclax plus acalabrutinib for adults with previously untreated CLL who need treatment.

  Recruiting at 114 sites Phase 3 BeOne Medicines · Duarte, California and 114 other locations · NCT07277231

• Intermittent versus continuous venetoclax with acalabrutinib in CLL/SLL

  This will test whether giving venetoclax intermittently or continuously together with acalabrutinib helps people with previously untreated CLL or SLL.

  Recruiting Phase 2 University of Cincinnati · Cincinnati, Ohio · NCT07014917

• Quality of life for people with CLL treated with acalabrutinib in France (PLATON database retrospective analysis)

  This project will test how quality of life changes during the first 12 months in adults with CLL who start acalabrutinib in real-world care in France.

  Recruiting AstraZeneca · Saint-Affrique · NCT06548152

• Evaluating the risk of tumor lysis syndrome in adults with chronic lymphocytic leukemia receiving venetoclax with obinutuzumab or acalabrutinib

  This study is testing if the combination of venetoclax with either obinutuzumab or acalabrutinib is safe for adults with untreated chronic lymphocytic leukemia.

  Recruiting at 69 sites Phase 3 AbbVie · Tucson, Arizona and 69 other locations · NCT06428019

• Comparing Nemtabrutinib to Ibrutinib or Acalabrutinib for First Line Treatment of Chronic Lymphocytic Leukemia

  This study is testing if a new drug called nemtabrutinib works as well as or better than two existing treatments for people with chronic lymphocytic leukemia who haven’t had treatment before.

  Recruiting at 181 sites Phase 3 Merck Sharp & Dohme LLC · Mobile, Alabama and 205 other locations · NCT06136559

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.